81_FR_54256 81 FR 54099 - Allergenic Products Advisory Committee; Notice of Meeting

81 FR 54099 - Allergenic Products Advisory Committee; Notice of Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 81, Issue 157 (August 15, 2016)

Page Range54099-54100
FR Document2016-19338

The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Allergenic Products Advisory Committee. The general function of the committee is to provide advice and recommendations to the Agency on FDA's regulatory issues. At least one portion of the meeting will be closed to the public.

Federal Register, Volume 81 Issue 157 (Monday, August 15, 2016)
[Federal Register Volume 81, Number 157 (Monday, August 15, 2016)]
[Notices]
[Pages 54099-54100]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-19338]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-N-0001]


Allergenic Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) announces a forthcoming 
public advisory committee meeting of the Allergenic Products Advisory 
Committee. The general function of the committee is to provide advice 
and recommendations to the Agency on FDA's regulatory issues. At least 
one portion of the meeting will be closed to the public.

DATES: The meeting will be held on October 27, 2016, from 1 p.m. to 
4:20 p.m.

ADDRESSES: FDA White Oak Campus, 10903 New Hampshire Ave., Building 31 
Conference Center, the Great Room (Rm. 1503), Silver Spring, MD 20993-
0002. Answers to commonly asked questions including information 
regarding special accommodations due to a disability, visitor parking, 
and transportation may be accessed at: http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm408555.htm.

FOR FURTHER INFORMATION CONTACT: Janie Kim or Denise Royster, Center 
for Biologics Evaluation and Research, Food and Drug Administration, 
10903 New Hampshire Ave., Bldg. 71, Silver Spring, MD 20993-0002, 301-
796-9016 or 240-402-8158, email: [email protected] or 
[email protected], or FDA Advisory Committee Information Line, 
1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in 
the Federal Register about last minute modifications that impact a 
previously announced advisory committee meeting cannot always be 
published quickly enough to provide timely notice. Therefore, you 
should always check the Agency's Web site at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the

[[Page 54100]]

appropriate advisory committee meeting link, or call the advisory 
committee information line to learn about possible modifications before 
coming to the meeting. For those unable to attend in person, the 
meeting will also be available via Web cast. The Web cast will be 
available at the following link: https://collaboration.fda.gov/apac1016/.

SUPPLEMENTARY INFORMATION: Agenda: On October 27, 2016, the committee 
will meet by teleconference. In open session, the committee will hear 
updates of research programs in the Laboratory of Immunobiochemistry of 
the Division of Bacterial, Parasitic and Allergenic Products (DBPAP), 
Office of Vaccines Research and Review, Center for Biologics Evaluation 
and Research, FDA.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting 
link.
    Procedure: On October 27, 2016, from 1 p.m. to 3:30 p.m., the 
meeting is open to the public. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Written submissions may be made to the contact person on 
or before October 13, 2016. Oral presentations from the public will be 
scheduled between approximately 2:30 p.m. and 3:30 p.m. Those 
individuals interested in making formal oral presentations should 
notify the contact person and submit a brief statement of the general 
nature of the evidence or arguments they wish to present, the names and 
addresses of proposed participants, and an indication of the 
approximate time requested to make their presentation on or before 
October 4, 2016. Time allotted for each presentation may be limited. If 
the number of registrants requesting to speak is greater than can be 
reasonably accommodated during the scheduled open public hearing 
session, FDA may conduct a lottery to determine the speakers for the 
scheduled open public hearing session. The contact person will notify 
interested persons regarding their request to speak by October 5, 2016.
    Closed Committee Deliberations: On October 27, 2016, the meeting 
will be closed from 3:35 p.m. to 4:20 p.m. to permit discussion where 
disclosure would constitute a clearly unwarranted invasion of personal 
privacy (5 U.S.C. 552b(c)(6)). The committee will discuss reports of 
intramural research programs and make recommendations regarding 
personnel staffing decisions.
    Persons attending FDA's advisory committee meetings are advised 
that the Agency is not responsible for providing access to electrical 
outlets.
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
disabilities. If you require accommodations due to a disability, please 
contact Janie Kim at least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: August 9, 2016.
Janice M. Soreth,
Acting Associate Commissioner, Special Medical Programs.
[FR Doc. 2016-19338 Filed 8-12-16; 8:45 am]
 BILLING CODE 4164-01-P



                                                                             Federal Register / Vol. 81, No. 157 / Monday, August 15, 2016 / Notices                                                  54099

                                                estimate it will take 5 hours to complete               MD 20910. The hotel’s phone number is                   Dated: August 8, 2016.
                                                Form FDA 3542.                                          301–589–0800.                                         Jeremy Sharp,
                                                   We estimate there will be 241                        FOR FURTHER INFORMATION CONTACT: Lori                 Deputy Commissioner for Policy, Planning,
                                                instances (based on an average of 114                   Benner and/or Jessica Barnes, Center for              Legislation and Analysis.
                                                NDAs filed and 127 NDA supplements                      Drug Evaluation and Research, Food                    [FR Doc. 2016–19336 Filed 8–12–16; 8:45 am]
                                                filed per year) where an NDA holder                     and Drug Administration, 10903 New                    BILLING CODE 4164–01–P
                                                would comply with the patent                            Hampshire Ave., Bldg. 22, Rm. 6221,
                                                declaration requirements. We estimate,                  Silver Spring, MD 20993–0002, 301–
                                                based on a proportional increase from                   796–1300.                                             DEPARTMENT OF HEALTH AND
                                                the number of declarations for approved                                                                       HUMAN SERVICES
                                                NDAs, that there will be an annual total                SUPPLEMENTARY INFORMATION: FDA is
                                                of 819 such declarations (241 × 3.4                     announcing a public workshop                          Food and Drug Administration
                                                declarations per instance = 819). Based                 regarding anti-infective drug
                                                                                                                                                              [Docket No. FDA–2016–N–0001]
                                                upon informal communications with                       development for neonates and young
                                                industry and our experience with the                    infants. Discussions will focus on                    Allergenic Products Advisory
                                                collection, we estimate it will take 20                 challenges related to enrolling neonates              Committee; Notice of Meeting
                                                hours to complete Form FDA 3542a.                       and young infants in clinical trials,
                                                                                                        strategies to assess central nervous                  AGENCY:    Food and Drug Administration,
                                                  Dated: August 5, 2016.                                system (CNS) penetration of the drug,                 HHS.
                                                Jeremy Sharp,                                           including nonclinical and in vitro data,              ACTION:   Notice.
                                                Deputy Commissioner for Policy, Planning,               potential development pathways, and
                                                Legislation, and Analysis.                              the role of clinical trial networks in anti-          SUMMARY:   The Food and Drug
                                                [FR Doc. 2016–19385 Filed 8–12–16; 8:45 am]             infective drug development in the                     Administration (FDA) announces a
                                                BILLING CODE 4164–01–P                                  neonatal population.                                  forthcoming public advisory committee
                                                                                                           Registration: Registration is free for             meeting of the Allergenic Products
                                                                                                        the public workshop. Interested parties               Advisory Committee. The general
                                                DEPARTMENT OF HEALTH AND                                are encouraged to register early. Seating             function of the committee is to provide
                                                HUMAN SERVICES                                          will be available on a first-come, first-             advice and recommendations to the
                                                                                                        served basis. To register electronically,             Agency on FDA’s regulatory issues. At
                                                Food and Drug Administration                                                                                  least one portion of the meeting will be
                                                                                                        email registration information
                                                                                                        (including name, title, firm name,                    closed to the public.
                                                [Docket No. FDA–2016–N–0001]                            address, telephone, and fax number) to                DATES: The meeting will be held on
                                                                                                        NeonatalAntibacterialWorkshop2016@                    October 27, 2016, from 1 p.m. to 4:20
                                                Facilitating Anti-Infective Drug                                                                              p.m.
                                                                                                        fda.hhs.gov. Persons without access to
                                                Development for Neonates and Young
                                                                                                        the Internet can call 301–796–1300 to                 ADDRESSES: FDA White Oak Campus,
                                                Infants; Notice of Public Workshop
                                                                                                        register.                                             10903 New Hampshire Ave., Building
                                                AGENCY:    Food and Drug Administration,                   If you need special accommodations                 31 Conference Center, the Great Room
                                                HHS.                                                    due to a disability, please contact Jessica           (Rm. 1503), Silver Spring, MD 20993–
                                                ACTION:   Notice of public workshop.                    Barnes or Lori Benner (see FOR FURTHER                0002. Answers to commonly asked
                                                                                                        INFORMATION CONTACT) at least 7 days in               questions including information
                                                SUMMARY:   The Food and Drug                            advance.                                              regarding special accommodations due
                                                Administration (FDA) is announcing a                       Agenda: The workshop draft Agenda                  to a disability, visitor parking, and
                                                public workshop regarding anti-                         will be made available at: http://                    transportation may be accessed at:
                                                infective drug development for neonates                 www.fda.gov/Drugs/NewsEvents/                         http://www.fda.gov/
                                                and young infants. FDA is interested in                 ucm507958.htm at least 2 days prior to                AdvisoryCommittees/
                                                discussing the scientific challenges                    the meeting. The Agency encourages                    AboutAdvisoryCommittees/
                                                pertaining to development of anti-                      individuals, industry, health care                    ucm408555.htm.
                                                infective products for neonates and                     professionals, researchers, public health             FOR FURTHER INFORMATION CONTACT:
                                                young infants. This public workshop is                  organizations and other interested                    Janie Kim or Denise Royster, Center for
                                                intended to provide information for and                 persons to attend this public workshop.               Biologics Evaluation and Research,
                                                gain perspective from health care                          Transcripts: Please be advised that as             Food and Drug Administration, 10903
                                                providers, other U.S. Government                        soon as a transcript is available, it will            New Hampshire Ave., Bldg. 71, Silver
                                                Agencies, public health organizations,                  be accessible at http://                              Spring, MD 20993–0002, 301–796–9016
                                                academic experts, and industry on                       www.regulations.gov. It may be viewed                 or 240–402–8158, email: Janie.Kim@
                                                various aspects of drug development for                 at the Division of Dockets Management                 fda.hhs.gov or Denise.Royster@
                                                new and currently marketed anti-                        (HFA–305), Food and Drug                              fda.hhs.gov, or FDA Advisory
                                                infective drugs for neonates and young                  Administration, 5630 Fishers Lane, Rm.                Committee Information Line, 1–800–
                                                infants. The input from this public                     1061, Rockville, MD 20852. A transcript               741–8138 (301–443–0572 in the
                                                workshop will also help in developing                   will also be available in either hardcopy             Washington, DC area). A notice in the
                                                topics for future discussion.                           or on CD–ROM, after submission of a                   Federal Register about last minute
                                                DATES: The public workshop will be                      Freedom of Information request. The                   modifications that impact a previously
sradovich on DSK3GMQ082PROD with NOTICES




                                                held on September 15, 2016, from 8:30                   Freedom of Information office address is              announced advisory committee meeting
                                                a.m. to 4:30 p.m. See the                               available on the Agency’s Web site at                 cannot always be published quickly
                                                SUPPLEMENTARY INFORMATION section for                   http://www.fda.gov. Transcripts will                  enough to provide timely notice.
                                                registration information.                               also be available on the Internet at:                 Therefore, you should always check the
                                                ADDRESSES: The public workshop will                     http://www.fda.gov/Drugs/NewsEvents/                  Agency’s Web site at http://
                                                be held at the Sheraton Silver Spring                   ucm507958.htm approximately 45 days                   www.fda.gov/AdvisoryCommittees/
                                                Hotel, 8777 Georgia Ave., Silver Spring,                after the workshop.                                   default.htm and scroll down to the


                                           VerDate Sep<11>2014   19:23 Aug 12, 2016   Jkt 238001   PO 00000   Frm 00059   Fmt 4703   Sfmt 4703   E:\FR\FM\15AUN1.SGM   15AUN1


                                                54100                        Federal Register / Vol. 81, No. 157 / Monday, August 15, 2016 / Notices

                                                appropriate advisory committee meeting                     Closed Committee Deliberations: On                 DATES:  Submit either electronic or
                                                link, or call the advisory committee                    October 27, 2016, the meeting will be                 written comments on this guidance at
                                                information line to learn about possible                closed from 3:35 p.m. to 4:20 p.m. to                 any time. General comments on Agency
                                                modifications before coming to the                      permit discussion where disclosure                    guidance documents are welcome at any
                                                meeting. For those unable to attend in                  would constitute a clearly unwarranted                time.
                                                person, the meeting will also be                        invasion of personal privacy (5 U.S.C.                ADDRESSES: You may submit comments
                                                available via Web cast. The Web cast                    552b(c)(6)). The committee will discuss               as follows:
                                                will be available at the following link:                reports of intramural research programs
                                                                                                        and make recommendations regarding                    Electronic Submissions
                                                https://collaboration.fda.gov/apac1016/.
                                                                                                        personnel staffing decisions.                           Submit electronic comments in the
                                                SUPPLEMENTARY INFORMATION:      Agenda:                    Persons attending FDA’s advisory                   following way:
                                                On October 27, 2016, the committee will                 committee meetings are advised that the                 • Federal eRulemaking Portal: http://
                                                meet by teleconference. In open session,                Agency is not responsible for providing               www.regulations.gov. Follow the
                                                the committee will hear updates of                      access to electrical outlets.                         instructions for submitting comments.
                                                research programs in the Laboratory of                     FDA welcomes the attendance of the                 Comments submitted electronically,
                                                Immunobiochemistry of the Division of                   public at its advisory committee                      including attachments, to http://
                                                Bacterial, Parasitic and Allergenic                     meetings and will make every effort to                www.regulations.gov will be posted to
                                                Products (DBPAP), Office of Vaccines                    accommodate persons with disabilities.                the docket unchanged. Because your
                                                Research and Review, Center for                         If you require accommodations due to a                comment will be made public, you are
                                                Biologics Evaluation and Research,                      disability, please contact Janie Kim at               solely responsible for ensuring that your
                                                FDA.                                                    least 7 days in advance of the meeting.               comment does not include any
                                                   FDA intends to make background                          FDA is committed to the orderly                    confidential information that you or a
                                                material available to the public no later               conduct of its advisory committee                     third party may not wish to be posted,
                                                than 2 business days before the meeting.                meetings. Please visit our Web site at                such as medical information, your or
                                                If FDA is unable to post the background                 http://www.fda.gov/                                   anyone else’s Social Security number, or
                                                material on its Web site prior to the                   AdvisoryCommittees/                                   confidential business information, such
                                                meeting, the background material will                   AboutAdvisoryCommittees/                              as a manufacturing process. Please note
                                                be made publicly available at the                       ucm111462.htm for procedures on                       that if you include your name, contact
                                                location of the advisory committee                      public conduct during advisory                        information, or other information that
                                                meeting, and the background material                    committee meetings.                                   identifies you in the body of your
                                                will be posted on FDA’s Web site after                     Notice of this meeting is given under              comments, that information will be
                                                the meeting. Background material is                     the Federal Advisory Committee Act (5                 posted on http://www.regulations.gov.
                                                available at http://www.fda.gov/                        U.S.C. app. 2).                                         • If you want to submit a comment
                                                AdvisoryCommittees/Calendar/                              Dated: August 9, 2016.                              with confidential information that you
                                                default.htm. Scroll down to the                         Janice M. Soreth,                                     do not wish to be made available to the
                                                appropriate advisory committee meeting                  Acting Associate Commissioner, Special
                                                                                                                                                              public, submit the comment as a
                                                link.                                                   Medical Programs.                                     written/paper submission and in the
                                                                                                        [FR Doc. 2016–19338 Filed 8–12–16; 8:45 am]
                                                                                                                                                              manner detailed (see ‘‘Written/Paper
                                                   Procedure: On October 27, 2016, from                                                                       Submissions’’ and ‘‘Instructions’’).
                                                1 p.m. to 3:30 p.m., the meeting is open                BILLING CODE 4164–01–P
                                                to the public. Interested persons may                                                                         Written/Paper Submissions
                                                present data, information, or views,                                                                             Submit written/paper submissions as
                                                orally or in writing, on issues pending                 DEPARTMENT OF HEALTH AND
                                                                                                                                                              follows:
                                                before the committee. Written                           HUMAN SERVICES                                           • Mail/Hand delivery/Courier (for
                                                submissions may be made to the contact                                                                        written/paper submissions): Division of
                                                                                                        Food and Drug Administration
                                                person on or before October 13, 2016.                                                                         Dockets Management (HFA–305), Food
                                                Oral presentations from the public will                 [Docket No. FDA–2014–D–0217]                          and Drug Administration, 5630 Fishers
                                                be scheduled between approximately                                                                            Lane, Rm. 1061, Rockville, MD 20852.
                                                2:30 p.m. and 3:30 p.m. Those                           Premarket Notification Submissions                       • For written/paper comments
                                                individuals interested in making formal                 for Electrosurgical Devices for General               submitted to the Division of Dockets
                                                oral presentations should notify the                    Surgery; Guidance for Industry and                    Management, FDA will post your
                                                contact person and submit a brief                       Food and Drug Administration Staff;                   comment, as well as any attachments,
                                                statement of the general nature of the                  Availability                                          except for information submitted,
                                                evidence or arguments they wish to                      AGENCY:    Food and Drug Administration,              marked and identified, as confidential,
                                                present, the names and addresses of                     HHS.                                                  if submitted as detailed in
                                                proposed participants, and an                           ACTION:   Notice of availability.                     ‘‘Instructions.’’
                                                indication of the approximate time                                                                               Instructions: All submissions received
                                                requested to make their presentation on                 SUMMARY:   The Food and Drug                          must include the Docket No. FDA–
                                                or before October 4, 2016. Time allotted                Administration (FDA or Agency) is                     2014–D–0217 for ‘‘Premarket
                                                for each presentation may be limited. If                announcing the availability of the                    Notification (510(k)) Submissions for
                                                the number of registrants requesting to                 guidance entitled ‘‘Premarket                         Electrosurgical Devices for General
                                                speak is greater than can be reasonably                 Notification (510(k)) Submissions for                 Surgery.’’ Received comments will be
sradovich on DSK3GMQ082PROD with NOTICES




                                                accommodated during the scheduled                       Electrosurgical Devices for General                   placed in the docket and, except for
                                                open public hearing session, FDA may                    Surgery.’’ FDA has developed this                     those submitted as ‘‘Confidential
                                                conduct a lottery to determine the                      guidance document to assist industry in               Submissions,’’ publicly viewable at
                                                speakers for the scheduled open public                  preparing premarket notification                      http://www.regulations.gov or at the
                                                hearing session. The contact person will                (510(k)) submissions for electrosurgical              Division of Dockets Management
                                                notify interested persons regarding their               devices intended for use in general                   between 9 a.m. and 4 p.m., Monday
                                                request to speak by October 5, 2016.                    surgery.                                              through Friday.


                                           VerDate Sep<11>2014   19:23 Aug 12, 2016   Jkt 238001   PO 00000   Frm 00060   Fmt 4703   Sfmt 4703   E:\FR\FM\15AUN1.SGM   15AUN1



Document Created: 2016-08-13 02:22:18
Document Modified: 2016-08-13 02:22:18
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice.
DatesThe meeting will be held on October 27, 2016, from 1 p.m. to 4:20 p.m.
ContactJanie Kim or Denise Royster, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Silver Spring, MD 20993-0002, 301- 796-9016 or 240-402-8158, email: [email protected] or [email protected], or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency's Web site at http://www.fda.gov/ AdvisoryCommittees/default.htm and scroll down to the appropriate advisory committee meeting link, or call the advisory committee information line to learn about possible modifications before coming to the meeting. For those unable to attend in person, the meeting will also be available via Web cast. The Web cast will be available at the following link: https://collaboration.fda.gov/ apac1016/.
FR Citation81 FR 54099 

2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR